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i.org/1transcatheter aortic valve implantation (TAVI). We report the feasibility and safety of early
discharge after TAVI with the Edwards SAPIEN-XT prosthesis. From 2009 to 2013, 337 pa-
tients underwent transfemoral TAVI with the Edwards SAPIEN-XT prosthesis using local
anesthesia andwere discharged homeeither early (£3days,EarlyDischarge group, n[ 121) or
after 3 days (Late Discharge group, n[ 216). The primary end point of the study combined
death and rehospitalization fromdischarge to30-day follow-up.Patients in theEarlyDischarge
group were less symptomatic (New York Heart Association class ‡III: 64.5% vs 75.5%, p[
0.01) andhad less renal failure (creatinine: 102.1– 41.0 vs 113.3– 58.9mmol/L, p[ 0.04), atrial
ﬁbrillation (33.1% vs 46.3%, p [ 0.02), and previous balloon aortic valvuloplasty (11.6% vs
23.1%, p[ 0.01) and were more likely to have a pacemaker before TAVI (16.5% vs 8.3%, p[
0.02). Pre-existingpacemaker (p[0.05) and the absenceof acute kidney injury (p[0.02)were
independent predictors of an early discharge, whereas previous balloon aortic valvuloplasty
(p[ 0.03) and post-TAVI blood transfusions (p[ 0.002) were independent predictors of late
discharge. The primary end point occurred in 4 patients (3.3%) in the Early Discharge group
and in 11 patients (5.1%) in the Late Discharge group (p[ 0.58). In conclusion, the results of
our study suggest that early discharge after transfemoral TAVI using the Edwards SAPIEN-
XT prosthesis is feasible and safe in selected patients.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2015;115:1116e1122)Since the First-In-Man transcatheter aortic valve im-
plantation (TAVI) in 2002, our group has been proposing a
progressive simpliﬁcation of TAVI procedures while keep-
ing patient safety as the main objective.1 We soon promoted
a “minimalist approach” for all transfemoral cases using
local anesthesia and ﬂuoroscopic guidance for valve
implantation without intraprocedural transesophageal
echocardiography.1e3 Since the launch of the SAPIEN-XT
device in October 2009 and the concomitant decrease in
sheath size to 16 F/20 F, most operators have switched to a
pure percutaneous approach. This further strengthened the
use of the “minimalist approach” for us and many other
operators and early discharge progressively emerged as a
reasonable option in the absence of procedural complica-
tions. There is currently no consensus on the duration of
monitoring required after TAVI.4 Prolonged hospitalization
often appears unnecessary, whereas shorter length of stay
with early return home may be beneﬁcial, particularly in oldf aCardiology and bThoracic and Cardiovascular Surgery,
Nicolle, University Hospital of Rouen, Rouen, France.
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0.1016/j.amjcard.2015.01.546and frail patients, and might also be cost effective. We,
therefore, aimed to evaluate the feasibility and safety of
early discharge after transfemoral TAVI.
Methods
We included all consecutive patients implanted with the
Edwards SAPIEN-XT valve through a transfemoral approach
(Edwards Lifesciences Inc., Irvine, California) from October
2009 to November 2013. The Heart Team established the
indication of TAVI according to the current guidelines. All
patients were included in national or international registries,
after approval of the corresponding Ethics Committee, and
provided signed informed consent.
The technique of transfemoral SAPIEN-XT valve im-
plantation using local anesthesia has been previously
described and reported by our group.3 After the procedure, all
the patients were monitored in the intensive care unit (ICU)
for at least 24 hours. Electrocardiography was recorded daily
until discharge, and transthoracic echocardiography was
performed before discharge. Patients were eligible for early
discharge if the procedure was not performed in emergency
and if there were no major complications during the proce-
dure and the ﬁrst 24 hours of monitoring in ICU (i.e., stroke,
myocardial infarction, major vascular complication requiring
transfusions, life-threatening bleeding, acute kidney injury
stage 2 or 3). Careful electrocardiographic monitoring inwww.ajconline.org
Figure 1. Bar graph representation of the distribution of length of stay in the overall population.
Figure 2. Bar graph representation of the proportion of early discharge from 2009 to 2013.
Figure 3. Bar graph representation of the mean length of stay from 2009
to 2013.
Valvular Heart Disease/Early Discharge and TAVI 1117ICU allowed for early conduction disturbances detection. A
pacemaker was systematically implanted in patients with
persistent complete atrioventricular block 24 hours after
TAVI. Patients with persistent de novo complete left bundle
branch block were also closely monitored and were not
eligible for early discharge. At discharge, patients were
advised to return to our department in case of worsening of
dyspnea, syncope, or any abnormal symptom. Thirty-day
outpatient visit and echocardiography were systematically
performed in all patients at our institution.
Baseline, procedural, and in-hospital data were entered
prospectively in the Rouen TAVI registry. Complications
and procedural outcomes were deﬁned according to the
Valvular Academic Research Consortium-2 consensus
statement.4 Clinical and transthoracic echocardiographic pa-
rameters were obtained at baseline, discharge, and 1 month.
Table 1
Baseline characteristics
Variables Overall
population
(n¼337)
Early
discharge
(n¼121)
Late
discharge
(n¼216)
P
Age (years) 84.0  6.8 83.7  6.9 84.2  6.2 0.46
Men 145 (43.0%) 58 (47.9%) 87 (40.3%) 0.17
Body mass index (kg/m2) 26.6  5.1 26.8  5.1 26.5  5.1 0.61
Hypertension 240 (71.2%) 89 (73.6%) 151 (69.9%) 0.56
Diabetes mellitus 101 (30.0%) 32 (26.4%) 69 (31.9%) 0.32
Previous myocardial infarction 34 (10.1%) 12 (9.9%) 22 (10.2%) 0.94
Previous percutaneous coronary intervention 75 (22.2%) 25 (20.7%) 50 (23.1%) 0.60
Previous coronary bypass 31 (9.2%) 11 (9.1%) 20 (9.3%) 0.96
Sinus rhythm 238 (70.6%) 94 (77.6%) 144 (66.6%) 0.04
History of atrial ﬁbrillation 140 (41.5%) 40 (33.1%) 100 (46.3%) 0.02
Right bundle branch block 43 (12.8%) 19 (15.7%) 24 (11.1%) 0.22
Pacemaker 38 (11.3%) 20 (16.5%) 18 (8.3%) 0.02
Previous balloon aortic valvuloplasty 64 (18.9%) 14 (11.6%) 50 (23.1%) 0.01
Peripheral artery disease 35 (10.4%) 15 (6.8%) 20 (9.3%) 0.37
Porcelain aorta 11 (3.3%) 5 (4.1%) 6 (2.8%) 0.50
Previous stroke 19 (5.6%) 7 (5.8%) 12 (5.6%) 0.93
Creatinine (mmol/l) 109.4  53.5 102.1  41.0 113.3  58.9 0.04
Creatinine clearance (ml/min) 47.0  22.4 50.9  24.7 44.9  20.8 0.02
Chronic obstructive pulmonary disease 59 (17.5%) 20 (16.5%) 39 (18.1%) 0.72
Chest irradiation 18 (5.3%) 8 (6.6%) 10 (4.6%) 0.44
Neoplasia 55 (16.3%) 19 (15.7%) 36 (16.7%) 0.80
NYHA III or more 241 (72.6%) 78 (64.5%) 163 (75.5%) 0.01
Logistic EuroSCORE (%) 16.9  9.6 15.6  9.6 17.6  9.5 0.07
Table 2
Baseline echocardiographic characteristics
Variables Overall
population
(n¼337)
Early
discharge
(n¼121)
Late
discharge
(n¼216)
P
Annulus diameter (mm) 21.5  2.3 21.6  2.0 21.5  2.5 0.93
Mean aortic gradient (mm Hg) 47.0  17.9 47.0  17.1 47.1  18.8 0.96
Aortic valve area (cm2) 0.64  0.24 0.61  0.25 0.65  0.24 0.12
Pulmonary artery systolic pressure (mm Hg) 44.8  14.9 44.4  12.9 45.0  15.8 0.77
Pulmonary artery systolic pressure ‡ 60 mm Hg 37 (11.0%) 8 (6.6%) 29 (13.4%) 0.19
Left ventricular ejection fraction (%) 59.0  16.3 59.7  16.3 58.7  16.3 0.61
Left ventricular ejection fraction < 30% 14 (4.2%) 2 (1.6%) 12 (5.6%) 0.10
1118 The American Journal of Cardiology (www.ajconline.org)The study population was divided into 2 groups based on
tertile length of stay values. Length of stay was calculated
from TAVI procedure (day 0) to discharge. Patients in the
lowest tertile (length of stay 3 days, n ¼ 121) constituted
the Early Discharge group, and patients with a length of stay
>3 days (n ¼ 216) constituted the Late Discharge group.
Qualitative variables were expressed as percentage, and
quantitative variables as mean  SD or median (25th to 75th
interquartile range). Comparison of numerical variables was
performed with the Student t test or Wilcoxon rank-sum test,
depending on variable distribution. The chi-square test or
Fisher’s exact test was used to compare qualitative variables.
A logistic regression multivariable analysis was used to
assess independent correlates of early discharge. The model
was built on the basis of the univariate association between
the variable and early discharge with a p ¼ 0.05 and an
elimination p ¼ 0.10. All statistical tests were 2 sided.
Differences were considered statistically signiﬁcant at ap value 0.05. All data were analyzed using SPSS software
(version 17.0; IBM, Armonk, New York).
Results
A total of 424 consecutive patients underwent TAVI using
the SAPIEN-XT prosthesis at our center in the speciﬁed
period. We excluded 65 patients implanted through trans-
apical or transaortic routes, 14 transfemoral patients who died
before 72 hours after implantation, and 8 patients who did not
return home directly but were transferred to a rehabilitation
center or another hospital. The ﬁnal study population
comprised 337 patients who returned home after discharge.
The distribution of length of stay after TAVI is shown in
Figure 1. One hundred twenty-one (36%) patients were dis-
charged within 3 days (Early Discharge group), whereas 216
(64%) were discharged >3 days after TAVI (Late Discharge
group). The proportion of patients with a length of stay
Table 3
Procedural outcomes
Variables Overall
population
(n¼337)
Early
discharge
(n¼121)
Late
discharge
(n¼216)
P
Valve size (mm) 0.23
23 154 (45.7%) 52 (43.0%) 102 (47.2%)
26 153 (45.4%) 54 (44.6%) 99 (45.8%)
29 30 (8.9%) 15 (12.4%) 15 (6.9%)
Valve-in-valve 5 (1.5%) 1 (0.8%) 4 (1.8%) 0.66
Procedural duration
(minutes)
102.4  46.4 83.4  43.8 110.6  45.5 0.02
X-ray time (minutes) 19.6  9.0 19.0  11.7 20.0  6.9 0.38
Contrast volume
(ml)
194.4  74.5 183.7  63.7 200.6  79.5 0.05
Table 4
Post-procedural echocardiographic characteristics
Variables Overall
population
(n¼337)
Early
discharge
(n¼121)
late
discharge
(n¼216)
P
Mean aortic gradient
(mm Hg)
10.3  4.5 10.3  4.4 10.2  4.5 0.78
Aortic valve area (cm2) 1.72  0.64 1.73  0.64 1.71  0.65 0.69
Aortic regurgitation
‡ Grade 2
78 (23.1%) 20 (16.5%) 58 (26.8%) 0.03
Pulmonary artery
systolic pressure
(mm Hg)
29.6  21.2 27.0  19.7 31.0  21.9 0.10
Left ventricular
ejection fraction (%)
59.0  16.3 60.7  15.2 62.0  14.5 0.47
Table 5
In-hospital outcomes
Variables Overall
population
(n¼337)
Early
discharge
(n¼121)
Late
discharge
(n¼216)
P
Stroke
Major stroke 4 (1.2%) 0 4 (1.9%) 0.14
Minor stroke 2 (0.5%) 0 2 (0.9%) 0.32
Transient ischemic
attack
2 (0.5%) 0 2 (0.9%) 0.32
Bleeding
Life-threatening 22 (6.5%) 0 22 (10.2%) <0.0001
Major 36 (10.7%) 6 (4.9%) 30 (13.8%) 0.01
Minor 25 (7.4%) 7 (5.8%) 18 (8.3%) 0.39
Transfusions 61 (18.1%) 3 (2.4%) 58 (26.8%) <0.0001
Acute kidney injury 0.01
Stage 3 2 (0.5%) 0 2 (0.9%)
Stage 2 1 (0.3%) 0 1 (0.4%)
Stage 1 50 (14.8%) 8 (6.6%) 42 (19.4%)
Vascular complications
Major 52 (15.4%) 7 (5.8%) 45 (20.8%) <0.0001
Minor 25 (7.4%) 8 (6.6%) 17 (7.8%) 0.70
Urgent vascular
surgery
4 (1.2%) 0 4 (1.9%) 0.30
Failure of closure
device
16 (4.7%) 1 (0.8%) 15 (6.9%) 0.002
Covered stent 28 (8.3%) 4 (3.3%) 24 (11.1%) 0.01
Peri-procedural
myocardial
infarction
2 (0.6%) 0 2 (0.9%) 1
Pacemaker 20 (5.9%) 4 (3.3%) 15 (6.9%) 0.13
Days from procedure
to Intensive Care
Unit discharge
Median (interquartile
range)
1 (1) 1 (1) 2 (2) <0.0001
Days from procedure
to discharge
Median (interquartile
range)
5 (4) 3 (1) 6 (4) <0.0001
Valvular Heart Disease/Early Discharge and TAVI 11193 days over the years is shown in Figure 2. Interestingly,
the incidence of early discharge gradually increased from 0%
in 2009 to 53.2% in 2013. In parallel, the mean length of stay
gradually decreased from 2009 to 2013 (Figure 3).
Baseline characteristics of the studied population are listed
in Tables 1 and 2. Patients in the Early Discharge group
had less renal failure and were more likely to have a history
of pacemaker. Moreover, they had less history of atrial
ﬁbrillation and balloon aortic valvuloplasty and were less
symptomatic. Other variables were comparable between the 2
groups.
Procedural and in-hospital outcomes are listed in Tables 3
to 5. Valve size and proportion of valve-in-valve procedures
were similar in the 2 groups. Procedural duration and contrast
volume were signiﬁcantly lower in the Early Discharge
group, whereas x-ray time was not signiﬁcantly different.
None of the patients in the Early Discharge group had stroke,
life-threatening bleeding, acute myocardial infarction, or
acute kidney injury stages 2 or 3 before discharge. Further-
more, patients in the Early Discharge group had less major
bleeding/vascular complications and transfusions. Other
variables were not signiﬁcantly different between the 2
groups. ICU stay was signiﬁcantly shorter in the Early
Discharge group. Postprocedural echocardiographic charac-
teristics are listed in Table 4. Mean aortic gradient and aortic
valve area were similar, whereas the proportion of patientswith an aortic regurgitation grade 2 was signiﬁcantly lower
in the Early Discharge group.
Univariate and multivariable analyses were performed to
identify predictive factors of early discharge and are listed in
Tables 6 and 7. Pre-existing pacemaker before TAVI and
absence of acute kidney injury were independent predictors
of an early discharge, whereas previous balloon aortic
valvuloplasty and post-TAVI blood transfusions were inde-
pendent predictors of a late discharge.
The primary end point occurred similarly between the 2
groups (Figure 4). No patient died in the Early Discharge
group. Two deaths occurred in the Late Discharge group
related to life-threatening bleeding and acute kidney injury
stage 3 in 1 case and to major stroke in the other case. The
proportion of patients readmitted within 30 days was low and
not signiﬁcantly different between the 2 groups. Importantly,
none of the patients discharged early presented with delayed
high degree atrioventricular block, whereas 1 patient in the
Late Discharge group was readmitted for symptomatic
bradycardia requiring pacemaker.
Table 6
Predictive factors of early discharge using univariate analysis
Variables Univariate analysis
Odd
ratio
95%
Conﬁdence
Interval
P
value
Transfusions 0.07 0.02-0.23 <0.0001
Major vascular complication 0.24 0.10-0.54 0.001
Covered stent 0.28 0.09-0.83 0.02
Left ventricular ejection fraction  30% 0.30 0.06-1.35 0.19
Life-threatening or major bleeding 0.32 0.13-0.80 0.01
Previous balloon aortic valvuloplasty 0.43 0.23-0.81 0.01
Atrial ﬁbrillation 0.53 0.35-0.98 0.04
NYHA  3 0.53 0.33-0.88 0.01
Aortic regurgitation  grade 2 post TAVI 0.54 0.31-0.95 0.03
Delta haemoglobin 0.58 0.47-1.72 0.11
Haemoglobin before TAVI 0.90 0.77-1.04 0.15
Creatinine clearance before TAVI 0.99 0.98-1.00 0.02
Delta creatinine 0.99 0.98-1.00 <0.0001
NT-pro brain natriuretic peptide 1.00 1.00-1.00 0.86
Age 1.01 0.98-1.04 0.46
Logistic EuroSCORE 1.02 1.00-1.05 0.07
Diabetes mellitus 1.32 0.81-2.17 0.27
Man 1.37 0.87-2.13 0.17
Sinus rhythm 1.72 1.03-2.86 0.04
Previous pacemaker 2.17 1.10-4.35 0.02
Delta haemoglobin was deﬁned as the difference between the haemo-
globin levels before the procedure and the nadir value after the procedure.
Delta creatinine was deﬁned as the difference between the creatinine
levels before the procedure and the highest value after the procedure.
Table 7
Predictive factors of early discharge using multivariable analysis
Variables Odd
ratio
95%
Conﬁdence
Interval
P
value
Transfusions 0.10 0.03-0.42 0.002
Previous balloon aortic valvuloplasty 0.44 0.22-0.91 0.03
NYHA 3 0.59 0.33-1.05 0.07
Atrial ﬁbrillation 0.65 0.35-1.19 0.16
Aortic regurgitation  grade 2 post TAVI 0.66 0.33-1.33 0.24
Major vascular complication 0.85 0.26-2.78 0.79
Delta creatinine 0.99 0.98-0.99 0.02
Creatinine clearance before TAVI 1.01 0.99-1.02 0.10
Logistic EuroSCORE 1.01 0.98-1.04 0.60
Previous pacemaker 2.27 1.01-5.26 0.05
Delta creatinine was deﬁned as the difference between the creatinine
levels before the procedure and the highest value after the procedure.
1120 The American Journal of Cardiology (www.ajconline.org)Discussion
The results of this study lead to the following conclusions:
(1) in an uncomplicated planned transfemoral procedure us-
ing Edwards SAPIEN-XT valve and local anesthesia, early
discharge is feasible and safe in selected patients and its
incidence increased gradually during the study period, to
reach eventually about half of our patients; and (2) previous
pacemaker, absence of previous balloon aortic valvuloplasty,
and transfusions after TAVI were independent predictors of
early discharge after TAVI.There is no consensus on the duration of monitoring
required after transfemoral TAVI and no published studies
evaluating the feasibility and safety of early discharge.
Furthermore, length of stay after TAVI is rarely reported in
most registries or randomized studies.5e14 In the French
National Transcatheter Aortic-Valve Implantation
(FRANCE-2) registry, the mean length of stay was 10.5 
8.1 days.8 Using a step-by-step simpliﬁcation of transfemoral
TAVI procedures, early discharge has emerged in our group
as a reasonable option considering the reduction of required
sheath size, a careful selection of patients avoiding compas-
sionate cases, and the growing experience of the operators.
Obviously, the occurrence of any major complication after
TAVI and TAVI performed in hemodynamically unstable
patients require prolonged recovery and do not allow an early
discharge. In our experience, most of the major complications
after Edwards SAPIEN-XT transfemoral TAVI occurred
within the ﬁrst 48 hours. Indeed, in our study, only 3 patients
presented with a delayed major complication (occurring from
discharge to 30 days): 1 case of transient ischemic attack and
1 case of acute kidney injury stage 3 in the Early Discharge
group and 1 case of life-threatening gastrointestinal bleeding
in the Late Discharge group. Moreover, occurrence of con-
duction disturbances including complete atrioventricular
block are immediate and more often temporary using the
Edwards Sapien-XT prosthesis. Our group and others pre-
viously reported a low incidence of persistent complete
atrioventricular block requiring permanent pacemaker using
the Edwards SAPIEN-XT prosthesis.15e17 Furthermore,
delayed (i.e., >24 hours after the procedure) high-grade
atrioventricular block has never been reported using the
Edwards SAPIEN-XT prosthesis. In contrast, with the
Corevalve, the incidence of complete atrioventricular block
requiring permanent pacemaker is higher, occurring in up to
25% of cases and can be delayed, thus requiring prolonged
electrocardiographic monitoring after TAVI.15e17
By multivariable analysis, the most powerful predictive
factor of early discharge failure was transfusions. Bleeding is
a frequent complication after TAVI and is mainly related to
femoral access and vascular complications at the puncture
site. Life-threatening and major bleedings occurred in 17.2%,
and transfusion of at least 1 red blood cell unit was necessary
in 18.1%. These results are in accordance with those previ-
ously reported by our group and others.18,19 Life-threatening
bleeding and postprocedural transfusions are independent
predictors of 30-day mortality and are associated with pro-
longed length of stay after TAVI.18 Bleeding after TAVI
could be decreased by careful selection of patients, smaller
size devices, and avoiding a loading dose of clopidogrel
before the procedure.20
Finally, early discharge after TAVI should have a signiﬁ-
cant economic impact. Cost-effectiveness of TAVI has been
previously evaluated in the randomized Placement of Aortic
Transcatheter Valves (PARTNER) trial.21,22 Compared with
medical management, it has been shown that TAVI increases
life expectancy and is a cost-effective treatment in inoperable
patients with severe aortic stenosis.21 Furthermore, compared
with surgical aortic valve replacement, 12-month costs were
slightly lower in the transfemoral cohort.22 Enlightening the
cost saving associated with minimalist strategy and early
discharge, Babaliaros et al23 recently demonstrated a cost
Figure 4. Bar graph representation of the combined primary end point including death and rehospitalization from discharge to 30-day follow-up in the Early
(black) and Conventional (white) Discharge groups.
Valvular Heart Disease/Early Discharge and TAVI 1121reduction of 10,000 US$ with the minimalist strategy in
comparison with the conventional approach in patients hos-
pitalized in the United States. Therefore, TAVI could be an
economically attractive strategy compared with surgical aortic
valve replacement for patients suitable for transfemoral access
and eligible for early discharge.
The results of our study are limited by its design, data
being obtained retrospectively from a single large volume
center with signiﬁcant expertise with TAVI. It is, therefore,
possible that other confounding unmeasured factors could
inﬂuence the results. Furthermore, we could not accurately
analyze the cause of “nonearly” discharge in patients who
did not have major complications. In particular, the auton-
omy of patient and any refusal by the patient and/or family
were not evaluated in this study. A prospective ongoing
study is, therefore, mandatory to conﬁrm the feasibility and
safety of early discharge after TAVI using the latest gen-
eration of balloon-expandable Edwards’s prosthesis and to
deﬁne the ideal candidates for that strategy.Disclosures
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